
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Michelle Hoiseth, Chief Data Officer for Parexel and Dr. GunjanRead More
The cost of developing a new drug roughly doubles everyRead More
In medicine, a Biomarker is a biological indicator, which canRead More
Digitalization is becoming a source of hope: new analyses, networking, and larger amounts of data could give a boost to drug development. “Data, data everywhere, but no drugs,” lamented Jerry Karabelas, the former pharmaceutical head of the Swiss Novartis Group. At that time, around the turn of the century, the pharmaceutical industry had been digging …
Big Pharma relies on Big Data to combat the research slump Read More »
How to build the foundations of AI your team needs?- A deep dive. Gaurav Tripathi, Co-Founder and CTO of Innoplexus, shares his experience as a data scientist and entrepreneur who embraces the challenges of AI. Learn about building the foundations of Life Sciences and Healthcare AI for continuous analytics by embracing failure in the right …
Eschborn, January 2019. The world-renowned US analyst firm Gartner Inc. annually publishes its Hype Cycle for Life Sciences to help C-Level understand innovative technology, prioritize investments and drive organizational change. The latest reported included Innoplexus AG, a leading provider of artificial intelligence (AI) for a second year in a row. Gartner sees Innoplexus as a …
INNOPLEXUS INCLUDED AGAIN IN GARTNER HYPE CYCLE FOR LIFE SCIENCES Read More »
Global AI firm Innoplexus launched an innovative blockchain platform to dramatically raise the amount of data available for drug research and discovery. This new platform, an update to Innoplexus’ flagship product iPlexus is the first of its kind and will enable researchers to upload and license unpublished data on the blockchain to facilitate collaboration, reduce …
Gunjan Bhardwaj helps pharmaceutical companies to find out more about diseases. By harnessing artificial intelligence, pharmaceutical companies are able to develop drugs more quickly. Frankfurt. It was a life-changing experience for Gunjan Bhardwaj to have a dear friend diagnosed with cancer years ago. In a desperate attempt to help, Bhardwaj, an Indian-born businessman, scavenged the …
Founder fights cancer with artificial intelligence Read More »
Indian and Swabian Together with friends from India, Gunjan Bhardwaj has successfully launched Innoplexus, a sophisticated ecosystem of continuous analytics, powered by artificial intelligence and machine learning.The goal: Innoplexus wants to become the European champion for AI. The chances: excellent. At 35, Gunjan Bhardwaj was an aspiring management consultant at Ernst & Young. The atmosphere …
Dr. Gunjan Bhardwaj is the founder and CEO of Innoplexus AG. With the help of artificial intelligence, blockchain and big data analysis applications, its iPlexus software has crawled over 300 terabytes of relevant clinical and medical data and put them in a logical context, being constantly updated and delivered to the workstations of customers in …